Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib + Phesgo versus placebo + Phesgo for PIK3CA-mutated HER2-positive advanced breast cancer
PACTR202402608766452Phase 3Recruiting
- Sponsor
- Roche
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of inavolisib and trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Investigator-Assessed Progression-Free Survival. Started Apr 2024; status: recruiting.
02
Drugs
inavolisibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202402608766452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402608766452.